ANI Pharmaceuticals to present eye implant data at AAO 2026 meeting

Go back to ANI Pharmaceuticals to present eye implant data at AAO 2026 meeting

ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting

September 30, 2026 6:55 AM EDT

Data from Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial will be presented in a late-breaking oral presentation during Uveitis Subspecialty Day 2026

Post-hoc analyses of baseline characteristics and efficacy outcomes in rescued and non-rescued patients from the Phase 4 NEW DAY trial will be presented in an on-demand ePoster

PRINCETON, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that data from SYNCHRONICITY, its Phase 4, open-label, single-arm clinical trial of Fluocinolone Acetonide Intravitreal Implant in patients with chronic non-infectious... More